BUSINESS WIRE: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the …

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

PARIS --(BUSINESS WIRE)-- 12.04.2014 --

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that a first set of results on phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity was presented on Saturday, April 12th, at the 8th World Congress for NeuroRehabilitation in Istanbul (Turkey).

Claude Bertrand, Executive Vice-President Research & Development and Chief Scientific Officer of Ipsen, commented: We are pleased that the first robust set of results from the phase III clinical study was presented by the Principal Investigator of the study (Pr JM Gracies) at this major congress. We look forward to sharing with the scientific community some additional data at coming international congresses.

Four weeks after Dysport injection, the Phase III clinical study results demonstrated that:

Additionally, patients treated with Dysport showed a higher proportion of responders from baseline in improved passive function versus placebo (exhibiting 1 grade decrease as measured by the disability assessment scale). At week 4, patients treated with Dysport 1000 units showed a statistically significant response rate of 62%. Patients treated with Dysport 500 units showed a clinically relevant response rate of 50%. Placebo arm showed a 39% response rate.

The safety profile observed in the study was consistent with the known safety profile of Dysport.

Further results from this double-blind study will be disclosed in the next few months at major international congresses.

For more detailed information about the 8th World Congress for NeuroRehabilitation, please see http://www.wcnr2014.org

See original here:
BUSINESS WIRE: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the ...